Table 1 Descriptive statistics of CAV1 tertiles in relation to clinicopathological factors in SCAN-B and METABRIC.
SCAN-B, all patients n = 5326 | METABRIC, all patients n = 1980 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
All | Miss-ing | CAV1 mRNA expression n = 5326 | All | Miss-ing | CAV1 mRNA expression n = 1980 | |||||
patients | Tertile 1 | Tertile 2 | Tertile 3 | patients | Tertile 1 | Tertile 2 | Tertile 3 | |||
n = 5326 | n = 1776 | n = 1775 | n = 1775 | n = 1980 | n = 660 | n = 660 | n = 660 | |||
Number (%) | Number (%) | Number (%) | Number (%) | Number (%) | Number (%) | Number (%) | Number (%) | |||
Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | |||||||
Age at diagnosis, years | – | 0 | – | – | – | 61.8 (51.4–70.6) | 0 | 64.1 (54.7–72.2) | 61.2 (50.8–70.6) | 60.1 (50.4–68.5) |
–40 | 270 (5.1) | 107 (6.0) | 98 (5.5) | 65 (3.7) | 143 (7.2) | 37 (5.6) | 47 (7.1) | 59 (8.9) | ||
41–50 | 874 (16.4) | 256 (14.4) | 368 (20.7) | 250 (14.1) | 327 (16.5) | 89 (13.5) | 121 (18.3) | 117 (17.7) | ||
51–60 | 1045 (19.6) | 328 (18.5) | 353 (19.9) | 364 (20.5) | 474 (23.9) | 142 (21.5) | 158 (23.9) | 174 (26.4) | ||
61–70 | 1661 (31.2) | 496 (27.9) | 530 (29.9) | 635 (35.8) | 565 (28.5) | 201 (30.5) | 181 (17.6) | 183 (27.7) | ||
71–80 | 995 (18.7) | 358 (20.2) | 285 (16.1) | 352 (19.8) | 367 (18.5) | 153 (23.2) | 116 (17.6) | 98 (14.8) | ||
81– | 481 (9.0) | 231 (13.0) | 141 (7.9) | 109 (6.1) | 104 (5.3) | 38 (5.8) | 37 (5.6) | 29 (4.4) | ||
Invasive tumor size | 166 | 23 | ||||||||
pT2/3/4 (> 20 mm) | 1783 (34.6) | 737 (42.8) | 550 (31.7) | 496 (28.9) | 1104 (56.4) | 401 (61.3) | 383 (58.9) | 320 (49.0) | ||
Axillary lymph node involvement | 213 | 0 | ||||||||
pN1/2/3 (any) | 1873 (36.6) | 674 (39.5) | 642 (37.7) | 557 (32.7) | 937 (47.3) | 322 (48.8) | 314 (47.6) | 301 (45.6) | ||
Main histological type | 37 | 44 | ||||||||
No special type (formerly ductal) | 4182 (79.1) | 1515 (85.8) | 1470 (83.3) | 1197 (68.1) | 1491 (77.0) | 544 (84.0) | 515 (79.1) | 432 (67.8) | ||
Lobular | 732 (13.8) | 114 (6.5) | 168 (9.5) | 450 (25.6) | 146 (7.5) | 28 (4.3) | 35 (5.4) | 83 (13.0) | ||
Other or mixed | 375 (7.1) | 136 (7.7) | 127 (7.2) | 112 (6.4) | 299 (15.4) | 76 (11.7) | 101 (15.5) | 122 (19.2) | ||
Histological grade | 382 | 84 | ||||||||
I | 791 (16.0) | 131 (7.9) | 256 (15.4) | 404 (25.0) | 169 (8.9) | 31 (4.9) | 57 (8.9) | 81 (12.9) | ||
II | 2443 (49.4) | 629 (37.8) | 854 (51.3) | 960 (59.4) | 772 (40.7) | 226 (35.6) | 250 (39.2) | 296 (47.4) | ||
III | 1710 (34.6) | 903 (54.3) | 554 (33.3) | 253 (15.6) | 955 (50.4) | 377 (59.5) | 330 (51.8) | 248 (39.7) | ||
Receptor Status | ||||||||||
ER+ | 4497 (85.2) | 49 | 1388 (78.7) | 1520 (86.3) | 1589 (90.6) | 1506 (76.1) | 0 | 496 (75.2) | 489 (74.1) | 521 (78.9) |
PR+ | 3725 (70.6) | 51 | 1123 (63.7) | 1282 (72.8) | 1320 (75.3) | 1040 (52.5) | 0 | 338 (51.2) | 332 (50.3) | 370 (56.1) |
HER2+ | 702 (13.6) | 149 | 301 (17.2) | 257 (15.0) | 144 (8.3) | 247 (12.5) | 0 | 101 (15.3) | 95 (14.4) | 51 (7.7) |
TNBC | 525 (10.4) | 64 | 258 (15.2) | 152 (9.1) | 115 (6.8) | 320 (16.2) | 0 | 113 (17.1) | 104 (15.8) | 103 (15.6) |
Systemic Treatments | 39 | 0 | ||||||||
Endocrine therapy | 3901 (78.2) | 1315 (75.5) | 1401 (80.2) | 1393 (79.4) | 1216 (61.4) | 393 (59.5) | 398 (60.3) | 425 (64.4) | ||
Chemotherapy | 2132 (42.7) | 912 (52.4) | 755 (43.2) | 576 (32.8) | 412 (20.8) | 127 (19.2) | 149 (22.6) | 136 (20.6) | ||
Trastuzumab | 555 (11.1) | 237 (13.6) | 217 (12.4) | 131 (7.5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
PAM50 Subtypes | 0 | 0 | ||||||||
Luminal A | 2555 (42.3) | 412 (23.2) | 857 (48.3) | 986 (55.5) | 660 (33.3) | 161 (24.4) | 228 (34.5) | 271 (41.1) | ||
Luminal B | 1275 (23.9) | 797 (44.9) | 397 (22.4) | 81 (4.6) | 526 (26.6) | 239 (36.2) | 179 (27.1) | 108 (16.4) | ||
Normal-like | 684 (12.8) | 14 (0.1) | 125 (7.0) | 545 (30.7) | 185 (9.3) | 9 (1.4) | 34 (5.2) | 142 (21.5) | ||
HER2 enriched | 641 (12.0) | 297 (16.7) | 259 (14.6) | 85 (4.8) | 278 (14.0) | 125 (18.9) | 119 (18.0) | 34 (5.2) | ||
Basal | 471 (8.8) | 256 (16.7) | 137 (7.7) | 78 (4.8) | 331 (16.7) | 126 (19.1) | 100 (15.2) | 105 (15.9) | ||
PAM50 ROR | 292 | 20 | ||||||||
Low | 1935 (38.4) | 183 (10.9) | 579 (34.5) | 1173 (70.1) | 402 (20.5) | 44 (6.7) | 119 (18.3) | 239 (36.5) | ||
Intermediate | 738 (14.7) | 237 (14.1) | 328 (19.5) | 173 (10.3) | 443 (22.6) | 137 (20.8) | 142 (21.8) | 164 (25.1) | ||
High | 2361 (46.9) | 1261 (75.0) | 773 (46.0) | 327 (19.5) | 1115 (56.9) | 475 (72.4) | 389 (59.8) | 251 (38.4) | ||
